DelSiTech signs License Agreement with Bayer Innovation
Under the terms of the agreement DelSiTech will receive a signing fee, milestone payments and further royalties for future sales of the products using the DelSiTech technology. The agreement contains also an option for further collaboration.
The DelSiTech ® drug delivery technology is a result of a cross-disciplinary project including researchers from the University of Turku and the Swedish-speaking University in Turku called Åbo Akademi. After the transfer of the technology, DelSiTech has started the industrialization process of the same. According to the compnay, it has been possible to encapsulate and controllably release extremely labile viruses and proteins to clinically useful applications by combining the in depth know-how and IPR of silica chemistry with the newest nano technology.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.